|
Market Closed -
Nasdaq
21:00:00 22/01/2026 GMT
|
5-day change
|
1st Jan Change
|
|
370.00 USD
|
+1.24%
|
 |
+2.99%
|
-6.95%
|
|
01-20 |
RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating
|
MT
| |
28/10/25 |
Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says
|
MT
| |
27/10/25 |
Doximity's Platform to Benefit From Advertisers' Shift to Healthcare Provider Channel, BofA Says
|
MT
| |
27/10/25 |
Intellia pauses gene therapy trials after patient suffers liver injury, shares slide
|
RE
| |
06/10/25 |
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating
|
MT
| |
29/09/25 |
Wall Street Bets Against Chaos, Again
|  | |
19/09/25 |
RBC Raises Price Target on Alnylam Pharmaceuticals to $500 From $435, Keeps Outperform Rating
|
MT
| |
04/08/25 |
Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says
|
MT
| |
04/08/25 |
Wolfe Upgrades Alnylam Pharmaceuticals to Peer Perform From Underperform
|
MT
| |
04/08/25 |
Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform From Market Perform, Price Target is $490
|
MT
| |
01/08/25 |
UBS Adjusts Price Target on Alnylam Pharmaceuticals to $550 From $403, Maintains Buy Rating
|
MT
| |
21/07/25 |
Truist Securities Initiates Coverage on Alnylam Pharmaceuticals With Buy Rating, $385 Price Target
|
MT
| |
07/07/25 |
RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating
|
MT
| |
02/05/25 |
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating
|
MT
| |
17/04/25 |
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating
|
MT
| |
24/03/25 |
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280
|
MT
| |
24/03/25 |
Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH…
| | |
21/03/25 |
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating
|
MT
| |
21/03/25 |
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating
|
MT
| |
25/02/25 |
Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...
| | |
24/02/25 |
Analyst recommendations: Unilever, Glencore, Tesla, XPO, Celanese Corp…
| | |
24/02/25 |
Analyst recommendations: Nike, Roku, Tesla, XPO, Celanese Corp...
| | |
21/02/25 |
Global Investors Eye New Shores
| | |
21/02/25 |
Analyst recommendations: Alphabet, Lear Corp, Molson Coors, Hasbro, Visa...
| | |
14/02/25 |
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
